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In the ionotropic glutamate receptor, the global con-
formational changes induced by partial agonists are
smaller than those induced by full agonists. However, in
the pentameric ligand-gated ion channel receptor fam-
ily, the structural basis of partial agonism is not under-
stood. This study investigated whether full and partial
agonists induce different conformation changes in the
glycine receptor chloride channel (GlyR). A substituted
cysteine accessibility analysis demonstrated previously
that glycine binding induced an increase in surface ac-
cessibility of all residues from Arg271 to Lys276 in the
M2-M3 domain of the homomeric 1 GlyR. Here we com-
pare the surface accessibility changes induced by the
full agonist, glycine, and the partial agonist, taurine. In
GlyRs incorporating the A272C, S273C, L274C, or P275C
mutation, the reaction rate of the cysteine-specific com-
pound, methanethiosulfonate ethyltrimethylammo-
nium, depended on how strongly the receptors were
activated but was agonist-independent. Reaction rates
could not be compared in the R271C and K276C mutant
GlyRs because methanethiosulfonate ethyltrimethylam-
monium did not modify the extremely small currents
induced by saturating taurine or equivalent low glycine
concentrations. The results indicate that bound taurine
and glycine molecules impose identical conformational
changes to the M2-M3 domain. We therefore conclude
that the higher efficacy of glycine is due to an increased
ability to stabilize a common activated configuration.
The glycine receptor chloride channel (GlyR)1 mediates fast
inhibitory neurotransmission in the vertebrate central nervous
system (1, 2). It belongs to the family of pentameric ligand-
gated ion channels (LGICs) that includes the nicotinic acetyl-
choline receptor (nAChR) as its prototypical member (3). Each
subunit incorporates a large N-terminal extracellular domain
and four -helical membrane-spanning domains. The second
membrane-spanning (M2) domains curve radially so as to form
a tapering, water-filled pore with a hydrophobic barrier (or
channel gate) at either its mid-point (4) or intracellular bound-
ary (5). The N-terminal domains contain the agonist-binding
sites and a disulfide loop that is an invariant feature of LGIC
receptors (6). Agonists binding in the N-terminal domain ini-
tiate conformational changes that propagate as a wave toward
the channel gate (7). Different agonists induce these conforma-
tional changes with different efficacies (where efficacy is the
ability of an agonist to open the channel once bound to the
receptor). If the efficacy of an agonist is sufficiently low, it will
behave as a partial agonist (8). The structural basis of differ-
ential agonist efficacy is not yet understood for any member of
the LGIC family.
Partial agonism could be caused by one, or a combination, of
the following two sharply contrasting mechanisms. First, it is
possible that different agonists induce different structural
changes throughout the protein. A clear example of this has
been characterized recently (9–11) in the ionotropic glutamate
receptor cation channel. These studies show that low efficacy
agonists induce a smaller degree of binding site core closure
than do high efficacy agonists, and show that this smaller
degree of closure is translated to the activation gate as a
smaller degree of channel opening (11). An alternative possi-
bility is that high and low efficacy agonists induce identical
global conformational changes but that the activated state is
more stable for the more efficacious agonist.
Glycine and taurine activate the GlyR with different effica-
cies; taurine has a low efficacy and generally behaves as a
partial agonist at this receptor, whereas glycine is a full agonist
(12). The present study seeks to establish whether or not tau-
rine and glycine induce identical conformational changes in a
domain that links the ligand-binding site to the activation gate.
This may provide insights into the structural basis of partial
agonist action at the GlyR.
The substituted cysteine accessibility method can quantitate
changes in protein conformation. The method entails introduc-
ing cysteine residues one at a time into a protein domain of
interest. The reactivity of these cysteines is then assayed by
exposure to highly soluble, sulfhydryl-specific reagents, gener-
ally methanethiosulfonate derivatives (13). If a functional
property of the channel is irreversibly modified upon exposure
to such a reagent, the cysteine is assumed to be exposed at the
water-accessible protein surface. Differences in the cysteine
modification rate between the closed and open states may
provide information about the associated structural changes.
Our laboratory previously used this approach to demonstrate a
glycine-induced increase in the surface exposure of six contin-
uous residues (Arg271–Lys276) in the GlyR M2-M3 linker do-
main (14). These residues lie mid-way between the binding site
and the activation gate (7), and it is now well established that
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they experience a conformational change that is crucial for the
activation of GlyRs (14–18), -aminobutyric acid, type A recep-
tors (19–24), and nAChRs (7, 25–27). A structural study of the
Torpedo nAChR has shown recently (4) that these residues
form an extramembranous extension to the M2 -helix. This
domain is likely to interact closely with loops 2 and 5 of the
ligand-binding domain (4, 17, 18, 23, 24). A particular advan-
tage of investigating this domain is that it lies outside the
ligand-binding pocket (6), so changes in methanethiosulfonate
reaction rates are unlikely to be influenced by steric effects of
ligand binding. The aim of the present study is to employ
substituted cysteine accessibility method to determine whether
or not glycine and taurine induce identical changes in the
surface accessibility of residues Arg271–Lys276.
MATERIALS AND METHODS
Mutagenesis and Expression of Human GlyR 1 Subunit
cDNAs—Site-directed mutations were incorporated into the human
GlyR 1 subunit cDNA in the pCIS2 vector using the QuickChange
mutagenesis kit (Stratagene, La Jolla, CA). The successful incorpora-
tion of the mutations was verified by cDNA sequencing. The WT and all
cysteine mutant GlyRs investigated in this study incorporated the
C41A mutation, which eliminated the only free external sulfhydryl
group. This mutation had no significant effect on GlyR EC50 values or
peak current magnitudes (14). The WT and mutant plasmid constructs
were transiently transfected into HEK293 cells using a modified cal-
cium phosphate precipitation method. After transfection for 24 h, the
cells were washed twice with cell culture medium, and electrophysi-
ological studies were conducted over the following 24–72 h.
Patch Clamp Electrophysiology—Glycine- and taurine-gated cur-
rents were measured using whole-cell recording at a holding potential
of 50 mV using an Axopatch 1D amplifier (Axon Instruments, Foster
City, CA), and data were directly recorded to disk using pCLAMP6
software (Axon Instruments). Cells were continually perfused at 2
ml/min with the standard bathing solution containing (in mM): 140
NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, pH 7.4. Patch
pipettes were heat-polished and had tip resistances of 2–4 megohms
when filled with the standard intracellular solution containing (in mM):
145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES, 10 EGTA, pH 7.4. At least 50%
of full series resistance compensation was applied in all recordings.
MTSET, obtained from Toronto Research Chemicals (Toronto, Can-
ada), was prepared as a stock solution of 10 mM in distilled water and
maintained on ice for up to 3 h until used. It was applied to cells within
30 s of being dissolved into room temperature bathing solution. The
disulfide-reducing agent, dithiothreitol (DTT), was prepared daily as a
1 mM solution in the standard bathing solution. This DTT-containing
solution had no irreversible effect on the magnitude of currents in the
WT GlyR. Solutions were applied to cells via a parallel system of
gravity-fed tubes, and solution exchange was effected with a time con-
stant of about 100 ms. Experiments were performed at room tempera-
ture (19–22 °C).
The effects of MTSET on glycine- and taurine-gated currents were
tested using the following procedure. Prior to MTSET application, cells
were bathed in 1 mM DTT for 1 min to ensure that exposed sulfhydryl
groups were fully reduced. Then the agonist dose response was meas-
ured by applying increasing agonist concentrations at 1-min intervals.
The relative magnitude of currents activated by saturating concentra-
tions of taurine and glycine was also measured. Following this, three
consecutive brief applications of a constant glycine concentration were
applied at 1-min intervals to establish that the current magnitude was
invariant (5%) prior to the application of MTSET. Following applica-
tion of the MTSET-containing solution, cells were washed in control
solution for at least 2 min before the maximum current magnitudes and
taurine EC50 values were measured again. If an irreversible effect was
observed, the MTSET concentration was adjusted so that the time
constant of the current response was between 0.3 and 20 s. The receptor
desensitization rate was low (0.005 s1) for all mutant GlyRs used in
this study and as such did not impact significantly on the measurement
of MTSET reactivity rates. It is estimated that a 10% irreversible
change in current over 1 min would have been reliably detected.
Data Analysis—Results are expressed as means  S.E. of four or
more independent experiments. The empirical Hill equation, fitted by a
non-linear least squares algorithm (Origin, Microcal, Northampton,
MA), was used to calculate the 50% effective concentrations for activa-
tion (EC50) and inhibition (IC50) and the Hill coefficient (nH) values.
Exponential fits were performed using the same non-linear least
squares algorithm. Statistical significance was determined by one-way
ANOVA using the Student-Newman-Keuls post hoc test for unpaired or
paired data as appropriate (Sigmastat, Jandel, San Rafael, CA), with
p  0.05 representing significance.
RESULTS
Characterization of Cysteine-substituted Mutant GlyRs—It
was shown previously that MTSET modification of cysteines
introduced into the N-terminal half of the M2-M3 domain (i.e.
from R271C to K276C) resulted in irreversible changes in the
glycine EC50 values without affecting the saturating current
magnitudes (14, 17). The same study also showed that the
MTSET reaction rate of all these cysteines was relatively slow
in the resting closed state but was increased dramatically in
the glycine-bound state. The aim of the present study is to
compare the effects of MTSET on the taurine-activated recep-
tor with its effects on the glycine-activated receptor.
The taurine agonist EC50 and nH values for the WT and all
cysteine-substituted mutant GlyRs examined in this study are
summarized in Table I. The taurine EC50 values for the A272C,
S273C, L274C, and P275C mutant GlyRs are significantly in-
creased relative to the WT value. Averaged glycine and taurine
dose responses for the WT and L274C mutant GlyRs are shown
in Fig. 1A. The peak magnitudes of taurine-gated currents
were too small to permit reliable EC50 measurement in the
R271C and K276C mutant GlyRs. The corresponding glycine
EC50 values for the WT and all mutant GlyRs, reproduced from
Lynch et al. (14), are included for comparison. The ratio of the
maximum current activated by taurine relative to that acti-
vated by glycine (Imax, tau/Imax, gly) for each mutant GlyR is also
shown (Table I). In calculating these ratios, the glycine- and
taurine-gated currents were both recorded from the same cell.
The cysteine substitution mutations invariably caused a signif-
icant reduction in this ratio. Thus, taurine behaves as a full
agonist in the WT GlyR but as a partial agonist relative to
TABLE I
Taurine activation and inhibition of cysteine-substituted mutant GlyRs
GlyR Glycine EC50
a
Taurine activation Taurine inhibition
EC50 nH Imaxtau/Imaxgly
b n IC50 nH Min Itau/Igly
c n
M mM mM
WT 18  2 0.12  0.03 1.6  0.1 1.03  0.06 6 3
R271C 2500  0.30d 0.06  0.01d 7 0.59  0.18 0.9  0.1 0.12  0.04d 4
A272C 2840  300d 10.2  0.40d 1.6  0.2 0.07  0.01d 5 0.87  0.10 1.1  0.2 0.16  0.04d 4
S273C 38  5d 0.71  0.06d 1.6  0.3 0.60  0.04d 9 3
L274C 395  10d 6.40  0.31d 1.5  0.1 0.14  0.02d 5 0.54  0.06 1.1  0.1 0.36  0.12d 4
P275C 1500  300d 15.3  1.20d 1.3  0.2 0.16  0.03d 6 1.46  0.38 1.0  0.2 0.08  0.04d 6
K276C 2714  482d 0.08  0.01d 5 0.59  0.10 0.8  0.2 0.12  0.04d 4
a From Lynch et al. (14)
b Imaxtau/Imaxgly represents the mean fraction of the saturating glycine-gated current activated by a saturating concentration (50 mM) of taurine.
c Min Itau/Igly represents the mean fraction of the half-saturating glycine-gated current remaining in the presence of 50 mM taurine.
d Significantly different with respect to WT GlyR.
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glycine in all mutant receptors examined.
The ability of taurine to inhibit currents activated by an
EC50 glycine concentration was also measured. An example of
taurine inhibition of EC50 (400 M) glycine currents in the
L274C GlyR is shown in Fig. 1B, and the inhibitory dose
response for this experiment, averaged from four cells, is shown
in Fig. 1C. The taurine IC50 and nH values for all tested mutant
GlyRs are summarized in Table I. The maximum extent to
which a saturating (50 mM) taurine concentration could inhibit
currents activated by an EC50 glycine concentration is pre-
sented in Table I as Min Itau/Igly. The taurine IC50 was invari-
ably around an order of magnitude lower than its EC50 in the
same mutant GlyR.
Steady-state Effects of MTSET—It has been demonstrated
previously that MTSET covalently modifies all introduced cys-
teines from R271C to K276C (14). This modification increased
the glycine EC50 of the P275C GlyR but decreased the glycine
EC50 of the remaining mutant GlyRs, all without affecting the
saturating glycine-gated current magnitude (14).
Fig. 2A shows examples of currents activated by saturating
concentrations of taurine and glycine in the R271C and L274C
GlyRs both before and after a 1-min MTSET application. In
these and all subsequent experiments, MTSET was applied at
a concentration of 100 M at the A272C, S273C, and L274C
GlyRs and at 200 M at the R271C, P275C, and K276C GlyRs.
These concentrations were chosen to yield reaction time con-
stants in an appropriate range (1–10 s) that was neither so
rapid as to be influenced by the solution exchange rate nor so
slow as to be influenced by receptor desensitization. In the
experiments summarized in Fig. 2, MTSET was applied in the
presence of a saturating (50 mM) concentration of taurine.
MTSET had no significant effect on the magnitude of currents
activated by a saturating glycine concentration in any of these
mutant GlyRs, consistent with previous findings (14). How-
ever, MTSET modification increased the peak magnitude of
taurine-gated currents in the L274C mutant GlyR but not in
the R271C GlyR (Fig. 2A). The effects of MTSET on the ratio of
saturating taurine- to glycine-gated currents (Imaxtau/Imaxgly)
were investigated in a similar manner for all mutant GlyRs,
and averaged results are summarized in Fig. 2B. MTSET sig-
FIG. 1. Examples of excitatory and inhibitory dose responses
for the WT and L274C GlyRs. A, averaged glycine and taurine exci-
tatory dose responses. For each receptor, glycine and taurine dose
responses were measured from the same cell, with the saturating gly-
cine current being set at 1 and the taurine current in the same cell
scaled accordingly. All dose responses are averaged from at least four
cells and parameters of best fit for taurine dose-responses are given in
Table I. B, an example of taurine inhibition of currents activated by an
EC50 (400 M) concentration of glycine. Both ligands were applied for
the periods as indicated by the bars. The traces correspond to taurine
concentrations of 100, 500 (labeled), 1000, 5000, and 20,000 M. C,
averaged taurine inhibitory dose response for the L274C GlyR. All
points are averaged from four cells, and the parameters of best fit are
given in Table I.
FIG. 2. Effects of MTSET on the relative peak magnitude of
taurine-gated currents. A, examples of currents activated by satu-
rating concentrations of taurine and glycine in R271C (upper panel) and
L274C (lower panel). Sample currents are shown both before (left panel)
and after (right panel) a 1-min application of MTSET  50 mM taurine.
MTSET was applied at a concentration of 100 M in the WT, A272C,
S273C, and L274C GlyRs and 200 M in the R271C, P275C, and K276C
GlyRs. Taurine and glycine were both applied at concentrations of 50
mM. B, the averaged ratio of peak taurine-gated currents to peak
glycine-gated currents (Imaxtau/Imaxgly) measured both before and after
exposure to MTSET  50 mM taurine. Each column represents the
average of at least four cells, and asterisks indicate a statistically
significant difference (p  0.05).
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nificantly increased this ratio in the A272C, S273C, and L274C
GlyRs, significantly decreased it in the P275C GlyR, and had
no effect on Imaxtau/Imaxgly in the R271C and K276C GlyRs.
Because MTSET functionally modified glycine-gated cur-
rents in the R271C and K276C GlyRs, its lack of effect on
taurine-gated currents appears to reveal a structural distinc-
tion between taurine- and glycine-gated currents. However, a
direct comparison requires that MTSET be applied in the pres-
ence of a glycine concentration that activates a current similar
in magnitude to that activated by a saturating taurine concen-
tration in the same cell. Examples of this experiment carried
out in the A272C, S273C, and P275C GlyRs are shown in Fig.
3A, and averaged results from all tested mutant GlyRs are
summarized in Fig. 3B. Together, these results indicate that
taurine- and glycine-gated currents were modified in a similar
manner by MTSET in all mutant GlyRs. Therefore, the steady-
state effect of MTSET does not depend on the agonist.
In those mutants where MTSET increased Imaxtau/Imaxgly (i.e.
A272C, S273C, and L274C), MTSET also significantly reduced
the taurine EC50. Examples of taurine dose responses before
and after a 1-min application of 100 M MTSET for the L274C
mutant GlyR are shown in Fig. 4A, and averaged results are
shown in Fig. 4B. MTSET caused a similar increase in taurine
sensitivity in the A272C and S273C GlyRs (Fig. 4C).
Because the peak magnitude of taurine-gated currents in the
P275C, K276C, and R271C GlyRs remained extremely low
after MTSET modification, it was not possible to directly de-
termine whether MTSET affected the taurine EC50 values.
However, it was possible to measure the effects of MTSET
modification on the potency of taurine inhibition of glycine-
gated currents. Progressively increasing concentrations of tau-
rine were applied to the P275C GlyR in the presence of an EC50
glycine concentration (Fig. 5A, upper panel). When this proce-
dure was repeated following a 1-min application of 100 M
MTSET  50 mM glycine, there was no apparent change in the
taurine inhibitory potency (Fig. 5A, lower panel). Because MT-
SET causes a 4-fold increase in the glycine EC50 (14), it was
necessary to increase the glycine concentration from 2 to 8 mM
to maintain half-maximum current activation. The results in-
dicate that MTSET modification had no effect on the taurine
IC50 for the P275C GlyR (Fig. 5B). The mean taurine IC50 and
nH values before and after MTSET modification are summa-
rized in Table II. Similar experiments were carried out on the
K276C and R271C GlyRs, and the results are also summarized
in Table II. Together, they suggest that MTSET modification
does not alter the affinity of these receptors for taurine.
The remainder of this study relies on the comparison of
MTSET reaction rates in the glycine- and taurine-activated
states. Such a comparison was not possible in the R271C and
K276C GlyRs as MTSET did not modify currents induced by
either saturating taurine or equivalent (EC5 to EC10) glycine
concentrations.
MTSET Reactivity Rates with A272C, S273C, L274C, and
P275C—Because differences in MTSET reaction rate can be
indicative of differences in receptor conformation, we compared
the MTSET reaction rates in the taurine- and glycine-bound
states in the A272C, S273C, L274C, and P275C mutant GlyRs.
It is important to note that the MTSET reaction rate in the
closed state is approximately an order of magnitude slower
than it is in the presence of EC30 glycine in all mutant GlyRs
tested here (10). An example of an experiment on the L274C
mutant GlyR is shown in Fig. 6A. Both panels in this figure
were recorded from the same cell. In Fig. 6A, taurine was
applied at a saturating concentration (50 mM), and MTSET was
applied at 100 M. The MTSET-induced current increase was
adequately described by a single exponential with a time con-
stant of 2.78 s. Currents recorded 2 min later confirm that
covalent modification has taken place (Fig. 6A, upper panel).
Following a 1-min exposure to 1 mM DTT, the experiment was
repeated using a glycine concentration (100 M) that activated
a current of similar magnitude to that activated by saturating
taurine (Fig. 6A, lower panel). MTSET modification of the
FIG. 3. Similar steady-state effects of MTSET on glycine- and
taurine-gated currents. A, in these experiments the glycine concen-
tration was chosen to activate a similar magnitude current as was
activated in the same cell by a saturating (50 mM) concentration of
taurine. (An exception is that a sub-saturating 200 M taurine concen-
tration was used in the S273C GlyR to avoid the problem of current
saturation prior to completion of the reaction. This issue is discussed
further in the text.) MTSET was then applied in the presence of the
same agonist concentration as was used to activate the control current.
Sample results are shown for the A272C, S273C, and P275C GlyRs. All
traces in each row were obtained from the same cell. B, averaged results
for the experiment shown in A. In each case, the percentage current
increase was calculated as (IMTSET/Icontrol  1)  100%. MTSET concen-
trations were the same as in Fig. 2A. The glycine concentrations were as
follows: R271C, 200 M; A272C, 200 M; S273C, 20 M; L274C, 100 M;
P275C, 100 M; K276C, 200 M. In the WT GlyR, 100 M MTSET was
applied in the presence of EC100 (1 mM) concentrations of glycine or
taurine. Using one-way ANOVA for paired data (p 0.05), there was no
significant difference in the effects of MTSET on taurine- and glycine-
gated currents in any tested GlyR.
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glycine-gated current proceeded with a time constant of 2.66 s.
The averaged time constants in the taurine- and glycine-acti-
vated states were 2.26  0.34 s (n  9 cells) and 2.06  0.43 s
(n  7 cells), respectively. There was no significant difference
between these values, indicating that the conformational
change experienced by Cys-274 depends on the fraction of peak
current activated, rather than the identity of the agonist.
In the S273C GlyR, the MTSET reactivity rate was examined
at the EC20 (200 M) taurine concentration. This sub-saturat-
ing taurine concentration was necessary as higher taurine EC
values would have resulted in current saturation prior to com-
pletion of the MTSET reaction, which in turn would have
distorted the apparent reaction rate. A glycine concentration of
20 M (EC10) was used to activate currents of similar magni-
tude in the same cell. Again, there was no significant difference
in MTSET reactivity between the taurine- and glycine-acti-
vated states (Fig. 6B).
The reaction rates of 100 M MTSET with A272C and P275C
were measured at saturating (50 mM) taurine concentrations
and glycine concentrations of 200 (EC10) and 100 M (EC10),
respectively. The averaged MTSET reaction rates in the tau-
rine- and glycine-bound states for all mutant GlyRs examined
in this study are also shown in Fig. 6B. Together, the results
indicate that the rate of the MTSET reaction with A272C,
S273C, L274C, and P275C does not depend on the identity of
the agonist.
FIG. 4. Effects of MTSET on the taurine EC50 of the A272C,
S273C, and L274C GlyRs. A, examples of taurine dose responses in
the L274C GlyR before and after exposure to 100 M MTSET. Both sets
of traces were from the same cell. B, taurine dose responses, measured
before and after MTSET exposure, averaged from five cells expressing
L274C GlyRs. C, mean taurine EC50 values before (open circles) and
after (filled circles) MTSET exposure for the A272C, S273C, and L274C
GlyRs. All points were averaged from at least four cells in which control
and MTSET-modified EC50 values were both measured.
FIG. 5. MTSET does not affect taurine inhibitory potency in
the P275C GlyR. A, examples of taurine inhibition of currents acti-
vated by EC50 glycine in the P275C GlyR both before (upper panel) and
after (lower panel) MTSET modification. Both sets of traces were from
the same cell. MTSET was applied at a concentration of 200 M for 1
min, and taurine was applied at concentrations of 0.1, 1 (labeled), 5, and
50 mM. B, taurine inhibitory dose responses averaged from four cells
both before (open symbols) and after (filled symbols) MTSET modifica-
tion. Averaged taurine IC50 and nH values of best fit are given in Table
II.
TABLE II
The effect of MTSET on taurine IC50 values for the R271C, P275C,
and K276C mutant GlyRs
GlyR
Control After MTSET n
IC50 nH IC50 nH
mM mM
R271C 0.59  0.18 0.9  0.1 0.47  0.10 0.7  0.3 4
P275C 1.46  0.38 1.0  0.2 1.04  0.01 1.2  0.3 4
K276C 0.59  0.10 0.8  0.2 0.62  0.12 0.8  0.3 4
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DISCUSSION
Two Models for Partial Agonism—Two sharply contrasting
models have been developed to describe the activation of oligo-
meric proteins, the coupled Monod-Wyman-Changeux (MWC)
model (34) and the uncoupled or sequential Koshland-Nem-
ethy-Filmer (KNF) model (35). In the simplest version of the
MWC model, all the subunits change conformation simulta-
neously, and in consequence the receptor can exist in only the
closed or entirely activated states. In contrast, the KNF model
proposes that each subunit can independently adopt a specific
conformation change depending on the number and species of
bound agonist molecules, leading to a series of intermediate
protein conformational states.
The structural basis of partial agonism in the ionotropic
glutamate receptor has been investigated using a combination
of crystallographic and electrophysiological techniques (11).
This study revealed that a series of partial agonists promoted a
range of conformational changes at the ligand-binding site,
with the magnitude of this structural change being directly
correlated with the probability of entering higher subconduc-
tance states. Thus, increasing agonist efficacy was manifested
by an increased ability to open the channel to its maximal
extent. This is a classic KNF-type mechanism.
Alternatively, partial agonism could also result from an
MWC-type model whereby high and low efficacy agonists in-
duce identical structural changes throughout the receptor. In
such a mechanism, higher efficacy would be manifested by an
increased ability to stabilize the open state. Because extended
MWC models can explain many characteristics of LGIC behav-
ior (34), this model is the favored hypothesis for the present
study.
Taurine as a Low Efficacy Agonist—By using classical recep-
tor theory (8), it can be shown that Fmax  E/(1  E), where
Fmax is the maximum fraction of receptors that can be activated
by a saturating agonist concentration, and E is the equilibrium
constant for gating (or efficacy). A combination of rapid agonist
application techniques and equilibrium single channel kinetic
analysis was used by Lewis et al. (12) to estimate E values of 16
and 3.4 for glycine and taurine, respectively, at the WT  GlyR.
According to these figures, taurine should activate around 77%
of the peak glycine current in the WT GlyR, although we find
taurine to be a full agonist of the WT GlyR. As summarized in
Table I, all mutant GlyRs examined in this study significantly
reduced this percentage. The above equation indicates that
variations in E have no measurable effect on peak current
magnitude unless they occur within a limited range of around
0.1 to 10. This means that a moderate reduction may not
significantly reduce the glycine Fmax, whereas any reduction in
the E would yield a reduction in the Fmax for taurine. Thus,
although the mutations examined in the present study reduced
the Fmax of taurine relative to glycine, they did not necessarily
exert a selective effect on taurine efficacy.
The fact that mutations converted taurine into a partial
agonist was convenient as it facilitated the comparison be-
tween the taurine- and glycine-activated states. For the pur-
poses of analyzing the structural basis of partial agonism, it
does not matter whether partial agonism was achieved by
appropriate choice of agonist, receptor mutagenesis, or a com-
bination of the two.
Prior to the present study little, if any, experimental evi-
dence was available concerning the structural basis of partial
agonism in pentameric LGICs. A variety of biochemical and
electrophysiological approaches have shown that the agonist-
binding pocket of LGIC receptors is formed by six discontinu-
ous domains, labeled A–F by Corringer et al. (28). The involve-
ment of these domains in forming the pocket has been
confirmed by the crystal structure of acetyl/choline binding
protein (6). In the GlyR, taurine and glycine both bind in this
cavity but appear to interact differently with at least one of the
molecular groups lining its wall (29–32). However, even if the
respective agonists induce different local structural changes at
the binding site, this does not necessarily imply that they
induce different global conformational changes (8).
Similarly, single channel kinetic analysis has not yet permit-
ted an unequivocal resolution of this issue. In the WT  GlyR,
FIG. 6. Comparison of MTSET modification rates in the tau-
rine- and glycine-bound states. A, comparison of the effect of 100 M
MTSET on currents activated by saturating (50 mM) taurine (upper
panel) and 100 M glycine (lower panel) in the same cell expressing
L274C GlyRs. MTSET applications were separated by a 2-min DTT
wash. Time constants of best fit are shown. B, averaged MTSET mod-
ification rates in the glycine-activated state (open circles) and taurine-
activated state (filled circles) for the indicated mutant GlyRs. Modifi-
cation rates were always compared at a common fraction of the peak
current magnitude as shown in A. For the S273C GlyR, taurine was
applied at a 200 M (EC20) concentration, and glycine was applied at a
20 M (EC10) concentration. In the remaining mutant GlyRs, taurine
was applied at a saturating (50 mM) concentration, and glycine was
applied at 200 M (A272C), 100 M (L274C), or 2 mM (P275C). All points
represent averages of 7–10 independent measurements. By using a
one-way ANOVA for paired data (p  0.05), there was no significant
difference in the MTSET reaction rates in the taurine- and glycine-
activated states for any tested mutant.
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the difference in E values between glycine and taurine was
explained by a difference in the channel opening rates, with the
closing rates being similar for both agonists (12). Although
these results suggest that glycine and taurine differ in their
abilities to stabilize the open state, they provide no information
about the underlying structural changes. In addition, taurine
and glycine have been shown to activate similar unitary con-
ductance levels (12). Again, this does not necessarily imply that
both agonists induce identical structural changes at the gate,
because the conductance of the open pore may be limited by
regions other than the gate (e.g. the M3-M4 domain (33)).
Comparison of MTSET Reaction Rates—MTSET has no ef-
fect on the magnitude of current activated by a saturating
glycine concentration (14), indicating that it does not alter the
GlyR single channel conductance or maximum open probabil-
ity. In the A272C, S273C, and L274C GlyRs, MTSET increased
Imaxtau/Imaxgly (Fig. 2B). It also reduced the EC50 values of
glycine and taurine to a similar extent (Fig. 4B; see also Fig. 5
in Ref. 14). MTSET had exactly the opposite effects on the
P275C GlyR. The reaction rates of MTSET with A272C, S273C,
L274C, and P275C were not significantly different for saturat-
ing taurine-gated currents and partially activating glycine-
gated currents, provided that the same current magnitude was
activated in the same cell (Fig. 6B). To interpret this result, it
is useful to consider the equation: I  n  i  Po, where I is the
macroscopic current, n is the total number of channels per cell;
i is the single channel conductance, and Po is the open proba-
bility. Because MTSET reaction rates were compared in the
same cell, n was a controlled variable in our experiments.
Furthermore, because the taurine and glycine single channel
conductances are identical (e.g. Ref. 12), i is also constant.
Indeed, it should be noted that full and partial agonists at all
pentameric LGIC members examined to date activate identical
unitary conductances. Thus, because the MTSET reaction rate
is proportional to the initial value of I, it must in turn be
proportional to Po. Therefore, the MTSET reaction rate simply
reflects the fraction of channels that are open and not the
number of occupied binding sites. This agrees with our recent
observation that the MTSET reaction rate with S273C did not
change significantly when the number of agonist-binding sites
per GlyR was reduced from 5 to 3 (36).
Because the M2-M3 domains are positioned mid-way along
the conformational “wave” that proceeds from the ligand-bind-
ing site to the channel gate (7), it must therefore be concluded
that binding site information is integrated prior to reaching the
M2-M3 domain. Hence, the ligand-induced inter-subunit coop-
erative interactions take place in the ligand-binding domain, in
accordance with the MWC model of receptor activation (34).
Mechanism of Taurine Inhibition—The taurine IC50 values
were not affected by MTSET in the R271C, P275C, or K276C
mutant GlyRs (Table II). Table I shows that taurine IC50 val-
ues are about 10 times lower than their corresponding EC50
values in those mutants where both can be measured. The
latter observation is consistent with a model where first tau-
rine binds with a high affinity (equal to the IC50 value) but is
unable to activate the channel. At least one additional taurine
must bind to a separate low affinity site (equal to the EC50
value) in order to open the channel. Because the homomeric
GlyR is likely to contain five identical taurine-binding sites (6),
this situation is most likely caused by negative cooperativity
among agonist-binding sites. It is likely that the cysteine sub-
stitutions create or enhance this negative cooperativity. A high
affinity for taurine inhibition would result if a single taurine
molecule can prevent the channel opening efficaciously when
the other binding sites are occupied by glycine. We propose that
MTSET does not affect the affinity of the first taurine-binding
reaction but increases the either the affinity of subsequent
agonist binding steps or the receptor gating efficacy.
CONCLUSIONS
This study compared the effects of MTSET on taurine- and
glycine-gated currents. In the A272C, S273C, L274C, and
P275C GlyRs, the MTSET reaction rate was a function of the
degree of receptor activation. The conformation and accessibil-
ity of this domain thus reflect the channel open probability and
convey no information about the identity or number of bound
agonist molecules. Therefore, partial agonism in the GlyR is
conferred by an MWC-like mechanism whereby partial and full
agonists induce similar conformational changes, with the
higher efficacy being due to an increased ability to stabilize the
open state. This is at variance with the mechanism of partial
agonism recently proposed for the glutamate receptor ion
channel.
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